In one of the studies, early breast cancer patients (age range, 55–70; mean age, 62.7 ± 4.1) suffering from urinary incontinence after the adjuvant endocrine therapy (estrogen, tamoxifen, and aromatase inhibitors) were asked to fill out the IIQ-7 and UDI-6 questionnaires, and the results were evaluated cross-sectionally. Here, CYP19A1 is linked to breast cancer.